Zosano Pharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Zosano Pharma Corporation (NASDAQ:ZSAN) announced that its Board of Directors granted a stock option to purchase 220,000 shares of common stock to a new employee as an inducement award.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zosano Pharma Corporation (NASDAQ:ZSAN) announced that its Board of Directors granted a stock option to purchase 220,000 shares of common stock to a new employee as an inducement award. The exercise price is set at $0.59 per share, matching the closing price on November 29, 2021. The stock option will vest 25% on the grant date, with the remainder vesting monthly thereafter. This action complies with Nasdaq Listing Rule 5635(c)(4).
Zosano focuses on developing rapid administration of approved molecules for underserved patient markets.
Positive
- Stock option grant of 220,000 shares as an inducement award to attract talent.
- Exercise price set at $0.59, aligning with market performance.
- Vesting schedule encourages retention and continued service of the new employee.
Negative
- None.
Details
News Market Reaction – ZSAN
The recorded move for ZSAN in the trading session of this news was +1.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FREMONT, Calif., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Board of Directors granted a stock option to purchase 220,000 shares of Zosano’s common stock to a new employee as an inducement award.
The stock option has an exercise price of
The award was approved in accordance with Nasdaq Listing Rule 5635(c)(4).
About Zosano Pharma
Zosano Pharma Corporation is a clinical-stage biopharmaceutical company focused on developing products where rapid administration of approved molecules with established safety and efficacy profiles may provide substantial benefit to patients, in markets where patients remain underserved by existing therapies. The company’s transdermal microneedle system technology consists of titanium microneedles coated with drug that are designed to enable rapid systemic administration of therapeutics to patients. Zosano’s lead product candidate is M207, which is a proprietary formulation of zolmitriptan designed to be delivered via its transdermal microneedle system technology, as an acute treatment for migraine. Learn more at www.zosanopharma.com.
Zosano Contacts:
Christine Matthews
Chief Financial Officer
510-745-1200
Zosano PR:
Sylvia Wheeler or Alexandra Santos
swheeler@wheelhouselsa.com or asantos@wheelhouselsa.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.